Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.28 HKD | -8.64% | +11.56% | -22.64% |
May. 28 | Hong Kong Stocks Stayed Flat Despite Shanghai’s Property Cuts, Beijing’s Huge Investment Plan | MT |
May. 28 | Alibaba Health Shares Rise on Earnings Beat | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- With an expected P/E ratio at 61.96 and 31.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-22.64% | 6.75B | B | ||
-37.88% | 13.99B | B- | ||
-33.12% | 10.67B | B | ||
+12.54% | 6.29B | C | ||
-11.17% | 5.88B | C+ | ||
+75.00% | 4.96B | C | ||
-4.38% | 4.54B | D- | ||
-9.20% | 3.74B | B | ||
-19.40% | 3.16B | C- | ||
-12.15% | 2.85B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 241 Stock
- Ratings Alibaba Health Information Technology Limited